Hypercoagulability State in Patients with Chronic Obstructive Pulmonary Disease

Summary

Since there is some clinical evidence that the clinical course of patients with chronic obstructive pulmonary disease (COPD) may be complicated by thrombosis in the pulmonary vessels, we studied whether a hypercoagulability state (HS) does occur in COPD. Plasma levels of prothrombin F1+2 fragment, a marker of thrombin generation, D-dimer, a marker of in vivo thrombin and plasmin activation, and fibrinogen were measured in 37 COPD patients and in 30 controls matched for sex and age. COPD patients had significantly higher values of F1+2 (p = 0.0001) and fibrinogen (p = 0.0005) than healthy subjects. The difference persisted after excluding smoking patients. F1+2 was not correlated with PaO₂ (r = 0.02, p >0.05) and PaCO₂ (p = 0.12, p >0.05). In six patients with stable COPD and F1+2 greater than 1.65 nM (mean + 2SD of controls) subcutaneous calcium-heparin therapy (5000 IU t.i.d. for 15 days) significantly reduced F1+2 (p = 0.03) and PaCO₂ (p = 0.01). This study shows that COPD patients have an ongoing prothrombotic state which could potentially account for thrombosis occurring in pulmonary vessels. The effect of calcium-heparin treatment on clotting system activation and blood gas may suggest this treatment as potential candidate for prospective study in COPD patients.

• References

• 1 Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: A pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42: 1163-1184
• 2 Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984; 70: 580-587
• 3 Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrino-peptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990; 82: 841-847
• 4 Brenner O, Birm MD, Long M. Sclerosis of pulmonary artery with thrombosis. Lancet 1931; 1: 911-914
• 5 Mitchell RS, Silver GW, Det GA, Petty TL, Vincent TW, Ryan SF, Filley GF. Clinical and morphologic complications in chronic airways obstructions. Am Rev Respir Dis 1968; 97: 54-62
• 6 Cordova C, Violi F, Alessandri C, Basili S, Barsi R, Saliola M, Paradiso M. Improvement of blood gas levels after calcium-heparin treatment in patients with chronic obstructive pulmonary disease. Thromb Res 1992; 68: 435-440
• 7 Pariente R, Cornu P, Wanstok E, Jeannin L, Drouet G. Interet du traitement anticoagulant ou cours des pousses d’insuffisance respiratoire aigue. Sem Hop (Paris) 1972; 48: 1333-1342
• 8 Steele P, Ellis JH, Genton HI. Platelet survival time in severe chronic airways obstruction. Chest 1975; 67: 46s-47s
• 9 Cordova C, Musca A, Violi F, Alessandri C, Perrone A, Balsano F. Platelet hyperfunction in patients with chronic airways obstruction. Eur J Resp Dis 1985; 66: 9-12
• 10 Johnson TS, Ellis JH, Steele P. Improvement of platelet survival time with oxygen in patients with chronic obstructive airways disease. Am Rev Resp Dis 1978; 117: 255-257
• 11 Cordova C, Musca A, Violi F, Perrone A, Alessandri C. Long-term oxygen and advanced chronic bronchitis. Lancet 1981; 1: 1098
• 12 Wedzicha JA, Syndercombe-Court D, Tan KC. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. Thorax 1991; 46: 504-507
• 13 Brun J, Perrin-Fayolle M, Gardere J, Pozzetto H, Biot N, Sab N. Syndromes d’hypercoagulabilite sanguine et thromboses cardiovasculaires au cours des insuffisances respiratoires chroniques. Press Med 1964; 72: 317-320
• 14 Bruhn HD, Conard J, Mannucci M, Monteagudo J, Pelzer H, Reverter JC, Samama M, Tripodi A, Wagner C. Multicentric evaluation of a new assay for prothrombin fragment Fl+2 determination. Thromb Haemost 1992; 68: 413-417
• 15 Pelzer H, Stuber W. Markers of hemostatic activation. Thromb Haemost 1989; 62: 165
• 17 Wilkes HC, Meade TW, Barzegar S, Foley AJ, Hughes LO, Bauer KA, Rosenberg RD, Miller GJ. Gemfibrozil reduces plasma prothrombin fragment Fl+2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost 1992; 67: 503-506
• 17 Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific Publications 1987
• 18 Le-Roux G, Larmignat P, Marchal M, Richalet JP. Haemostasis at high altitude. Int J Sports Med 1992; 13 (1): S49-S51
• 19 Gertler JP, Weibe DA, Ocasio VH, Abbott WM. Hypoxia induces procoagulant activity in cultured human venous endothelium. J Vase Surg 1991; 13 (3): 428-433
• 20 Ogawa S, Sheeniwas R, Brett J, Clauss M, Furie M, Stern DM. The effect of hypoxia on capillary endothelial cell function: modulation of barrier and coagulant function. Br J Haematol 1990; 75 (4): 517-524
• 21 McGee MP, Wallin R, Wheeler FB, Rothberg H. Indication of the extrinsic pathway of coagulation by human and rabbit alveolar macrophages: a kinetic study. Blood 1989; 74: 1583-1590
• 22 Nakstad B, Lyberg T, Skjonsberg OH, Boye NP. Local activation of the fibrinolysis system in lung disease. Thromb Res 1990; 57: 827-838
• 23 Lyberg T, Nakstad B, Hetland O, Boye NP. Procoagulant (thromboplastin) activity in human bronchoalveolar lavage fluids is derived from alveolar macrophages. Eur Resp J 1990; 3: 61-67
• 24 Di Minno G, Mancini M. Drugs affecting plasma fibrinogen levels. Cardio-vasc Drugs Ther 1992; 6 (1): 25-7